
Reformation
REFNewly listed · final prospectus verifiedReformation Inc. · NYSE · Apparel retail · latest filing 2026/07/30
Newly listed — review valuation, deal quality and post-IPO supply before acting
Reformation Inc. began trading on 2026-07-30 at an IPO price of $15.00; the final prospectus and offer terms are linked to SEC EDGAR.
🔒 Detailed transaction interpretation is available with Pro- Business and development direction
A direct-to-consumer and store-based seller of women's apparel and accessories.
Current business Apparel retail100%
Future development Future direction not yet disclosedNot quantified

SEC source document
The filing's first page is kept visible in the overview so the issuer, document type and filing basis can be checked before reading the analysis.
- Document
- 424B4
- Filed
- 2026/07/30
- Source
- SEC EDGAR
Three risks and three checkpoints
Valuation and future tradable supply require continued review
🔒 The evidence, figures, severity and remaining risk review are available with Pro.
- 1J.P. Morgan Securities LLC——
- 2Morgan Stanley & Co. LLC——
- 3Citigroup Global Markets Inc.——
- 4RBC Capital Markets, LLC——
- 5Guggenheim Securities, LLC——
- 6Robert W. Baird & Co. Incorporated——
- 7William Blair & Company, L.L.C.——
- 8BTIG, LLC——
- 9Telsey Advisory Group LLC——
Where each offered share directs value
IPO valuation scenario simulator
Adjustable assumptions are visible after unlocking.
424B4 · 2026/07/30
- Voting
- Economic
- As of
- 2026/07/30
Next public checkpoint:First post-IPO filing and lock-up schedule
- Initial float
- Potential float
- Multiple
- Increase
Evidence completeness and operating runway
Final prospectus, offer price, listing date and headline financial evidence reconciled
Valuation and future tradable supply require continued review
- Potential impact
- Monitor
- First post-IPO filing and lock-up schedule
- Evidence
- 424B4 · 2026/07/30
- Potential impact
- Monitor
- Evidence
- 424B4 · 2026/07/30
- Potential impact
- Monitor
- Evidence
- 424B4 · 2026/07/30
Unlock each change, investor impact and evidence locator
What remains missing16% of the evidence set remains unresolved. This may affect unconfirmed pricing, valuation, dilution or supply conclusions; no missing term is estimated.
View the filing's actual first page +
